- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Collaboration to Simplify Document Exchange in Clinical Trials
TransCelerate BioPharma Inc., a non-profit organization with membership comprised of global biopharmaceutical companies, has partnered with Veeva Systems on the Shared Investigator Platform (SIP), a platform that facilitates investigative site collaboration with multiple clinical trial sponsors. The TransCelerate SIP Initiative aims to provide the industry with a centralized platform that will be interoperable with various clinical solutions, streamline communications between investigators and sponsors, and reduce redundant requests during a trial. It will use the Veeva Vault SiteExchange to improve efficiencies and allow clinical trial investigators, sites, and participating sponsors to have immediate and centralized access to critical documents, eliminating one of the burdens that exists at investigator sites. For more information on the collaboration, visit https://www.veeva.com/eu/industry-collaborations/
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
